Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
June’s first Dispatch reaches patients
Dispatch Bio’s virus therapy DV-10 enters phase 1.
Astra’s Datroway biomarker gives and it takes away
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Pluvicto gets a no in Europe
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
